

1124/05



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	-		Application Number	10/714,591	
			Filing Date	November 14, 2003	
	TRANSMITTAL		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN	
	FORM		Group Art Unit	1616	
	(to be used for all correspondence after initial t	filing)	Examiner Name	Not yet assigned	
	Total Number of Pages in This Submission	5	Attorney Docket Number	GANG-006	
	*	NCLOSUR	ES (check all that apply)		
	Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Supplemental Information Disclosure Statement & SB08a Form (4 pgs.) Certified Copy of Priority Documents Response to Missing Parts/ Incomplete Application	Assection (for for for for for for for for for for	signment Papers r an Application) awing(s) ensing-related Papers tition tition to Convert to a ovisional Application wer of Attorney, Revocation ange of Correspondence dress rminal Disclaimer quest for Refund	After Allowance Communication to Group Appeal Communication to Boar of Appeals and Interferences Appeal Communication to Grou (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter	rd
	Response to Missing Parts under 37 CFR 1.52 or 1.53				
	SIGNATU	RE OF APPL	ICANT, ATTORNEY, OR	RAGENT	
Signing a (Reg. No Signatur	Attorney/Agent CAROL L. FRANCIS, 3 BOZICEVIC, FIELD 8	6,513	0.0		
Date	January 21, 2005	your	\int		

EXPRESS MAIL LABEL NO. EV 519869358 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No. EV 519869358 US

SUPPLEMENTAL	Attorney Docket	GANG-006
INFORMATION	First Named Inventor	RAMACHANDRAN,
DISCLOSURE STATEMENT	Application Number	10/714,591
OIPE	Confirmation No.	3234
Address to:	Filing Date	November 14, 2003
Mail Stan JAN 2 9 2008	Group Art Unit	1616
Commissioner for Patents	Examiner Name	Not yet assigned
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "BACTERIOP AND USES T	HAGE HAVING MODIFIED HOLIN HEREOF"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. GANG-006 may be charged thereon.

Respectfully submitted,

Registration-No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP

BOZICEVIC, FIELD & FRANCIS LLP

1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\GANG\006\Suppl ids filed.doc

PTO/SB/03a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, repersons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PEO JAN 2 1 2005

INFORMATION DISCLASURE
STATEMENT BY APPLICANT

Sheet

(ilea ae manu chaate ae naraecaru)

of

3

Complete if Known				
Application Number	10/714,591			
Filing Date	November 14, 2003			
First Named Inventor	RAMACHANDRAN, JANAKIRAMAN			
Art Unit	1616			
Examiner Name Not yet assigned				
Attorney Docket Number	GANG-006			

Examiner Initials'	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ² (if known)			Figures Appear
		US- 4,957,686	09/18/1990	Norris	
		US- 5,688,501	11/18/1997	Merril, et al.	
		US- 6,121,036	12/19/2000	Ghanbari, et al.	
		US- 6,264,945	07/24/2001	Fischetti et al.	
		US2002/005802	05/16/2002	Nelson et al.	

		FOREIG	N PATENT DO	UMENTS		
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code 3-Number 4-Kind Code 5(If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		WO 95/31562	11/23/1995	Quest International B.V.		
		WO 95/27043	10/12/1995	Exponential Biotherapies, Inc.		
		WO 01/82945	11/8/2001	New Horizons Diagnostic Corporation		
		GB 829266 A	03/02/1960			
		EP 0403292 A2	06/14/1990	Microbial Development Limited		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²	
		Blasi et al. "Two beginnings for a single purpose: the dual-start holins in the regulation of phage lysis" Mol Microbiol. 1996 Aug;21(4):675-82		
		Blasi et al. "The C-terminal sequence of the lambda holin constitutes a cytoplasmic regulatory domain." J Bacteriol. 1999 May; 181(9):2922-9		

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		C	Complete if Known		
				Application Number	10/714,591
	INFORMATION DIS	CLOS	SURE	Filing Date	November 14, 2003
	STATEMENT BY A	PPLIC	ANT	First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
				Art Unit	1616
	(uea ae manu chaate ae naracearu)			Examiner Name	Not yet assigned
Sheet	2	of	3	Attorney Docket Number	GANG-006

Carlton, "Phage therapy: past history and future prospects", R. M., Arch. Immunol. Ther. Exp., 47, 267(1999)
Dressman et al. "Lysis and lysis inhibition in bacteriophage T4: rV mutations reside in the holin t gene" J Bacteriol. 1999 Jul;181(14):4391-6
Grundling et al. "Holins kill without warning" Proc. Natl. Acad. Sci. USA 98:9348-52 (2001)
Hori et al "Construction of self-disruptive <i>Bacillus</i> megaterium in response to substrate exhaustion for polyhydroxybutyrate production", Appl Microbio. Biotech 2002 59 211-216
Johnson-Boaz et al. "A dominant mutation in the bacteriophage lambda S gene causes premature lysis and an absolute defective plating phenotype", Mol Microbiol. 1994 Aug;13(3):495-504
 Jain et al. "Use of lambda phage s and r gene products in an inducible lysis system for <i>vibrio</i> cholerae- and salmonella enteica serovar typhimurium-based DNA vaccine delivery systems", Infect Immun, 68, 986-89 (2000).
Kutter, "Bacteriophage Therapy," at www.evergreen.edu/phage/phagetherapy/phagetherapy.html, last updated 07/14/2004
Merrill et al "Long-circulating bacteriophage as antibacterial agents", (Proc. Natl. Acad. Sci. USA 93, 3188 (1996)
Miller et al. "Bacteriophage T4 genome", Microbiol Mol Biol Rev. (2003) 67(1):86-156
Martin et al. "Functional analysis of the two-gene lysis system of the Pneumococcal phage Cp-1 in homologous and heterolgous host cells" J. Bacteriol. 180:210-7 (1998)
Ramanculov et al. "Functional analysis of the phage T4 holin in a lambda context," Mol. Genet. Genomics 265:345-53 (2001)
Ramanculov et al. "Genetic analysis of the T4 holin: timing and toplogy" Gene 265:25-36 (2001)

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

-	Substitute for form 1449A/PTO				omplete if Known
Substitute	e for form 1449A/PTO			Application Number	10/714,591
l	INFORMATION DISC	CLOS	URE	Filing Date	November 14, 2003
:	STATEMENT BY APPLICANT			First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
				Art Unit	1616
	luca ac manu chaate ac n	ودععمم	n/l	Examiner Name	Not yet assigned
Sheet	3	of	3	Attorney Docket Number	GANG-006

Sulakvelidze et al. "Minireview Bacteriophage Therapy", Antimicrob Agents Chemotherap, vol. 45, no. 3, pg. 649-659 (2001)
Sanders et al "A chloride-inducible gene expression cassette and its use in induced lysis of <i>lactococcus lactis</i> ", Appl Environ. Microbiol. 1997 63 4877-82
Smith et al. "Purification and biochemical characterization of the lambda holin" J Bacteriol. 1998 May;180(9):2531-40
Tan et al. "Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile." J Med Microbiol. 2001 Jul;50(7):613-9
Vukov et al. "Functional analysis of heterologous holin proteins in a lambdaDeltaS genetic background." FEMS Microbiol Lett. 2000 Mar 15;184(2):179-86;
Wang et al. "Holins: the protein clocks of bacteriophage infections." Annu Rev Microbiol. 2000;54:799-825
Young, "Bacteriophage holins: deadly diversity." J Mol Microbiol Biotechnol. 2002 Jan;4(1):21-36

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.